Anktiva Immunotherapy Research Advances
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.100
Low
5.00
Averages
7.33
High
9.00
Current: 8.100
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors and could severely impact the company's reputation and stock price.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is under scrutiny for the class period from January 19, 2026, to March 24, 2026, where investors allege that executives overstated Anktiva's capabilities, leading to misleading positive statements about the company's prospects, potentially affecting future funding and market trust.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues and potential restructuring, which could undermine shareholder confidence and lead to stock volatility.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz before the deadlines to understand their legal rights in these class actions, highlighting the significant legal risks these companies face that may impact their future operations and financial health.
See More
ImmunityBio Investors Alert for Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti LLC alerts investors who purchased ImmunityBio shares between January 19, 2026, and March 24, 2026, that they must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: Following a warning letter from the FDA regarding misleading cancer therapy advertisements, ImmunityBio's stock price plummeted by 21% on March 24, 2026, translating to a $1.98 loss per share, indicating significant market concerns over the company's compliance and transparency.
- Legal Accountability: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could result in substantial legal and financial repercussions for the company.
- Investor Rights: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm to express their interest in participating in the lawsuit, ensuring their rights are protected.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which may have misled investors about the company's prospects and affected its stock price.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's operations.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the class action, emphasizing the importance and urgency of investor rights in legal proceedings.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, and missing this date may affect their rights to claim.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is facing legal challenges, and the investigation by Faruq & Faruqi aims to assist investors in understanding their rights and potential legal avenues in this case.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, indicating potential legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, underscoring its commitment to protecting investor rights and its expertise in the legal field.
See More
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors and could severely impact the company's reputation and stock price.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is under scrutiny for the class period from January 19, 2026, to March 24, 2026, where investors allege that executives overstated Anktiva's capabilities, leading to misleading positive statements about the company's prospects, potentially affecting future funding and market trust.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues and potential restructuring, which could undermine shareholder confidence and lead to stock volatility.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz before the deadlines to understand their legal rights in these class actions, highlighting the significant legal risks these companies face that may impact their future operations and financial health.
See More
ImmunityBio Investors Alert for Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti LLC alerts investors who purchased ImmunityBio shares between January 19, 2026, and March 24, 2026, that they must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: Following a warning letter from the FDA regarding misleading cancer therapy advertisements, ImmunityBio's stock price plummeted by 21% on March 24, 2026, translating to a $1.98 loss per share, indicating significant market concerns over the company's compliance and transparency.
- Legal Accountability: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could result in substantial legal and financial repercussions for the company.
- Investor Rights: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm to express their interest in participating in the lawsuit, ensuring their rights are protected.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which may have misled investors about the company's prospects and affected its stock price.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's operations.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the class action, emphasizing the importance and urgency of investor rights in legal proceedings.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, and missing this date may affect their rights to claim.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is facing legal challenges, and the investigation by Faruq & Faruqi aims to assist investors in understanding their rights and potential legal avenues in this case.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, indicating potential legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, underscoring its commitment to protecting investor rights and its expertise in the legal field.
See More
